vimarsana.com

Page 4 - பல்கலைக்கழகம் ஆஃப் ஐயுவா கார்வர் கல்லூரி மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stupidly Painful, Debilitating Menstrual Period Could Be A COVID-19 Vaccine Side Effect: Report

Stupidly Painful, Debilitating Menstrual Period Could Be A COVID-19 Vaccine Side Effect: Report KEY POINTS A woman from New York City reported experiencing painful menstrual cramps after getting the COVID-19 vaccine Experts explained that this is an isolated incident and that side effects are common in any vaccine Common side effects of the COVID-19 vaccine include fatigue, nausea, headaches and fever Abigail, a 29-year-old from New York City, reported experiencing “stupidly painful, debilitating” menstrual cramps after getting vaccinated aginst COVID-19. Although there is currently no evidence to link the menstrual pain she felt to the COVID-19 vaccine, Abigail believes that the Pfizer-BioNTech shot was what triggered her cramps.

IDPH answers questions about COVID-19 vaccine in virtual seminar

IDPH answers questions about COVID-19 vaccine in virtual seminar We want to be able to give you the information you need to understand why it s so important to get a vaccine. And it s safe and effective, says Dr. Caitlin S. Pedati with Iowa Dept. of Public Health. Share Updated: 9:35 PM CDT Apr 19, 2021 IDPH answers questions about COVID-19 vaccine in virtual seminar We want to be able to give you the information you need to understand why it s so important to get a vaccine. And it s safe and effective, says Dr. Caitlin S. Pedati with Iowa Dept. of Public Health. Share

Case Western Reserve and Atelerix Life Sciences Inc sign option license to develop new therapeutic approach to opioid crisis

Date Time Share Case Western Reserve and Atelerix Life Sciences Inc. sign option license to develop new therapeutic approach to opioid crisis Novel small molecule technology reverses life-threatening opioid-induced respiratory depression without diminishing pain relief Case Western Reserve University and Atelerix Life Sciences Inc., a Charlottesville, Virginia-based biotechnology company, have signed a two-year option to license a novel family of small molecules called Active Thiol-Based Compounds (ATBC’s) to prevent or reverse life-threatening opioid-related side effects. The lead compound, ATLX-0199 (also called sudaxine), will be first targeted at opioid-induced respiratory depression (OIRD) in the hospital setting. A recent study by the medical technology company Medtronic found that 46% of surgical patients receiving opioids for post-operative pain-relief suffer one or more episodes of OIRD, presenting perhaps the most significant obstacle to discharge from intensive ca

CWRU, Atelerix sign option license to develop therapeutic approach to opioid crisis

CWRU, Atelerix sign option license to develop therapeutic approach to opioid crisis CWRU, Atelerix sign option license to develop therapeutic approach to opioid crisis Print Case Western Reserve University and Atelerix Life Sciences Inc., a Charlottesville, Va.-based biotechnology company, have signed a two-year option to license novel, small-molecule technology to prevent or reverse life-threatening opioid-related side effects, according to a news release. A recent study by medical technology company Medtronic found that 46% of surgical patients receiving opioids for post-operative pain relief suffer one or more episodes of opioid-induced respiratory depression (OIRD), presenting a significant obstacle to discharging patients from intensive care units and the hospital, the release stated.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.